{"id":"cannabidiol-oral-solution","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Somnolence"},{"rate":"20-25","effect":"Diarrhea"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Decreased appetite"},{"rate":"10-15","effect":"Elevated liver transaminases"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cannabidiol (CBD) is a non-intoxicating cannabinoid that interacts with multiple molecular targets including TRPV1 channels, 5-HT1A receptors, and GPR55, while also modulating endocannabinoid tone. Its anticonvulsant properties are thought to arise from enhancement of GABAergic inhibition, reduction of excitatory glutamatergic transmission, and anti-inflammatory effects in the central nervous system. The exact mechanism remains incompletely understood but involves both cannabinoid receptor-dependent and receptor-independent pathways.","oneSentence":"Cannabidiol modulates endocannabinoid signaling and multiple other pathways to reduce seizure activity and provide neuroprotective effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:52.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seizures associated with Dravet syndrome"},{"name":"Seizures associated with Lennox-Gastaut syndrome"},{"name":"Seizures associated with tuberous sclerosis complex"}]},"trialDetails":[{"nctId":"NCT06512389","phase":"PHASE2","title":"Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-08-16","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT06381791","phase":"PHASE1, PHASE2","title":"CBD for Pain Following Orthopedic Shoulder Surgery","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2024-05-24","conditions":"Shoulder Osteoarthritis, Rotator Cuff Injuries","enrollment":80},{"nctId":"NCT06113237","phase":"","title":"Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-08-05","conditions":"Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse","enrollment":50},{"nctId":"NCT06924827","phase":"PHASE4","title":"A Study to Investigate the Transition of Children From 'Artisanal\" Cannabidiol (CBD) to Epidiolex","status":"NOT_YET_RECRUITING","sponsor":"Elizabeth Donner","startDate":"2026-06-01","conditions":"Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)","enrollment":25},{"nctId":"NCT05044819","phase":"PHASE4","title":"Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-07-07","conditions":"Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex","enrollment":154},{"nctId":"NCT05864846","phase":"PHASE4","title":"A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2023-06-29","conditions":"Tuberous Sclerosis Complex Associated Neuropsychiatric Disease","enrollment":79},{"nctId":"NCT07233239","phase":"PHASE1","title":"A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-11-26","conditions":"Focal Seizures","enrollment":100},{"nctId":"NCT07459920","phase":"PHASE2","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2026-04-01","conditions":"Advanced Malignant Solid Tumor","enrollment":156},{"nctId":"NCT07462559","phase":"PHASE1","title":"KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2026-03-04","conditions":"Drug Drug Interaction","enrollment":12},{"nctId":"NCT07123467","phase":"PHASE3","title":"Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2025-11-03","conditions":"Generalized Anxiety Disorder (GAD), Anxiety Disorders","enrollment":90},{"nctId":"NCT05961501","phase":"PHASE2, PHASE3","title":"The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin","status":"ENROLLING_BY_INVITATION","sponsor":"Wroclaw Medical University","startDate":"2025-04-01","conditions":"Myalgia, Muscle Pain, Orofacial Pain","enrollment":42},{"nctId":"NCT05651607","phase":"PHASE2","title":"Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-09-07","conditions":"Hereditary Epidermolysis Bullosa","enrollment":10},{"nctId":"NCT07434973","phase":"PHASE3","title":"Stratification and Treatment in Early Psychosis Study - PROMOTE","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-05-01","conditions":"Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis","enrollment":586},{"nctId":"NCT06333041","phase":"PHASE2, PHASE3","title":"Study of Cannabidiol in Sanfilippo Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2026-03-15","conditions":"Sanfilippo Syndrome, Mucopolysaccharidosis III","enrollment":35},{"nctId":"NCT06234631","phase":"PHASE2","title":"Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty","status":"RECRUITING","sponsor":"Chad Brummett","startDate":"2024-03-13","conditions":"Knee Replacement Surgery, Osteoarthritis, Knee","enrollment":380},{"nctId":"NCT05485831","phase":"","title":"Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY","status":"RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2025-02-24","conditions":"Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex","enrollment":100},{"nctId":"NCT04978428","phase":"PHASE2","title":"Epidiolex in Obsessive Compulsive Disorder and Related Disorders","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2022-04-14","conditions":"Obsessive-Compulsive Disorder, Trichotillomania (Hair-Pulling Disorder), Tourette Syndrome","enrollment":4},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05066308","phase":"PHASE2","title":"Cannabidiol for Reduction of Brain Neuroinflammation","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-01-04","conditions":"Back Pain, Depressive Symptoms","enrollment":80},{"nctId":"NCT05052541","phase":"PHASE3","title":"Safety and Efficacy of Oral Cannabis in Chronic Spine Pain","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-01","conditions":"Back Pain, Neck Pain","enrollment":157},{"nctId":"NCT07298408","phase":"PHASE1, PHASE2","title":"Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Florida A&M University","startDate":"2026-01-02","conditions":"Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies","enrollment":20},{"nctId":"NCT04411225","phase":"PHASE3","title":"Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2022-06-01","conditions":"Early Psychosis","enrollment":120},{"nctId":"NCT07326124","phase":"PHASE3","title":"Stratification and Treatment in Early Psychosis Study -ASSIST","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-06","conditions":"Treatment Resistant Psychosis, Psychosis","enrollment":250},{"nctId":"NCT05644262","phase":"PHASE2","title":"Life's End Benefits of cannaBidiol and tetrahYdrocannabinol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-12-18","conditions":"Agitation, Dementia","enrollment":120},{"nctId":"NCT07278505","phase":"PHASE1, PHASE2","title":"Study of Cannabidiol and Neuroimaging on Stress","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-10-28","conditions":"Early Life Adversity, Trauma, Stress","enrollment":160},{"nctId":"NCT06778564","phase":"PHASE3","title":"Stratification and Treatment in Early Psychosis Study - ENHANCE","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2026-02","conditions":"Psychosis, First Episode Psychosis, Psychotic Disorders","enrollment":250},{"nctId":"NCT06787118","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-12","conditions":"Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":130},{"nctId":"NCT07199218","phase":"PHASE2","title":"Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism","status":"RECRUITING","sponsor":"Bazelet Nehushtan LtD.","startDate":"2025-10-05","conditions":"Autism, Autism Spectrum Disorder","enrollment":78},{"nctId":"NCT07224932","phase":"PHASE2","title":"Tolerability and Efficacy of CBD Extract for RLS Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-19","conditions":"Restless Leg Syndrome","enrollment":60},{"nctId":"NCT05885542","phase":"PHASE1, PHASE2","title":"SCORE Emerging Adult Cannabis Use & Stress","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-01","conditions":"Cannabis Use Disorder","enrollment":148},{"nctId":"NCT04485104","phase":"PHASE3","title":"Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-05-19","conditions":"Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome","enrollment":3},{"nctId":"NCT04567784","phase":"PHASE2","title":"Neuroimaging and CBD for Opioid Use Disorder","status":"COMPLETED","sponsor":"Yasmin Hurd","startDate":"2020-11-12","conditions":"Heroin Abuse, Opioid Use Disorder, Substance-Related Disorders","enrollment":66},{"nctId":"NCT05494788","phase":"PHASE2","title":"Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)","status":"COMPLETED","sponsor":"Cardiol Therapeutics Inc.","startDate":"2023-01-09","conditions":"Recurrent Pericarditis","enrollment":27},{"nctId":"NCT04517799","phase":"PHASE2","title":"Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2020-06-01","conditions":"Autism, Autism Spectrum Disorder","enrollment":42},{"nctId":"NCT04821856","phase":"PHASE2","title":"Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-05-11","conditions":"Intellectual Disability, Child Behavior Problem","enrollment":132},{"nctId":"NCT06192589","phase":"PHASE1","title":"Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2024-02-08","conditions":"Cannabidiol, Drug Induced Liver Injury, Drug Interaction","enrollment":241},{"nctId":"NCT05269628","phase":"PHASE2","title":"Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype","status":"RECRUITING","sponsor":"Tiffany J. Braley, MD, MS","startDate":"2022-03-25","conditions":"Multiple Sclerosis, Sleep, Pain","enrollment":166},{"nctId":"NCT04721691","phase":"PHASE1","title":"Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2021-03-10","conditions":"Electrical Status Epilepticus of Slow-Wave Sleep","enrollment":16},{"nctId":"NCT04754399","phase":"PHASE2","title":"Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-04-16","conditions":"Arthralgia, Breast Cancer","enrollment":40},{"nctId":"NCT05772429","phase":"","title":"Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2023-04-17","conditions":"Seizures","enrollment":158},{"nctId":"NCT04745026","phase":"PHASE2","title":"Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-05-31","conditions":"Autism Spectrum Disorder","enrollment":103},{"nctId":"NCT04428203","phase":"PHASE1","title":"Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer","status":"COMPLETED","sponsor":"Zin W Myint","startDate":"2020-08-03","conditions":"Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma","enrollment":21},{"nctId":"NCT06261450","phase":"PHASE2","title":"Effect of CBD on the Brain","status":"NOT_YET_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-05-01","conditions":"Fragile X Syndrome","enrollment":50},{"nctId":"NCT06261502","phase":"PHASE2","title":"Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2025-05-01","conditions":"Fragile X Syndrome","enrollment":40},{"nctId":"NCT05514899","phase":"PHASE2","title":"Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-09-01","conditions":"HIV, Cannabis, THC","enrollment":90},{"nctId":"NCT04749628","phase":"PHASE4","title":"Cannabidiol for Bilateral Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-02","conditions":"Pain, Postoperative, Opioid Use, Knee Osteoarthritis","enrollment":37},{"nctId":"NCT05288283","phase":"PHASE3","title":"Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2022-10-31","conditions":"Seizures Associated With EMAS","enrollment":3},{"nctId":"NCT05823753","phase":"PHASE2","title":"Cannabidiol to Reduce Anxiety Reactivity","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2023-04-19","conditions":"Social Anxiety, Social Anxiety Disorder","enrollment":63},{"nctId":"NCT05600114","phase":"PHASE2","title":"Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder","status":"COMPLETED","sponsor":"EmpowerPharm Inc.","startDate":"2022-10-27","conditions":"Social Anxiety Disorder","enrollment":239},{"nctId":"NCT04280289","phase":"EARLY_PHASE1","title":"CBD Cannabis Extract: Pharmacokinetic Studies","status":"COMPLETED","sponsor":"University of Mississippi, Oxford","startDate":"2021-02-01","conditions":"Epilepsy","enrollment":10},{"nctId":"NCT06105138","phase":"NA","title":"Cannabidiol Effects on Blood Alcohol Level and Intoxication","status":"COMPLETED","sponsor":"Colorado State University","startDate":"2021-03-09","conditions":"Alcohol Use Disorder","enrollment":37},{"nctId":"NCT05132699","phase":"PHASE1, PHASE2","title":"Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2022-04-04","conditions":"Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic","enrollment":21},{"nctId":"NCT03904849","phase":"PHASE1, PHASE2","title":"Cannabidiol for Alcohol Use Disorder","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","startDate":"2019-10-01","conditions":"Alcohol Use Disorder","enrollment":""},{"nctId":"NCT03582137","phase":"PHASE2","title":"A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2018-09-05","conditions":"Parkinson Disease","enrollment":74},{"nctId":"NCT04603391","phase":"PHASE4","title":"Cannabidiol and CES1 Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-25","conditions":"Drug Interaction","enrollment":14},{"nctId":"NCT06393101","phase":"PHASE1","title":"The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-06-01","conditions":"Complex Regional Pain Syndrome","enrollment":52},{"nctId":"NCT03900923","phase":"PHASE2","title":"Cannabidiol for ASD Open Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-03-12","conditions":"ASD, Autism Spectrum Disorder","enrollment":29},{"nctId":"NCT05097651","phase":"PHASE2","title":"CBD for Sleep in People With HIV","status":"WITHDRAWN","sponsor":"Mariana Cherner, PhD","startDate":"2021-04-01","conditions":"Sleep Disturbance","enrollment":""},{"nctId":"NCT03676049","phase":"","title":"Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)","status":"AVAILABLE","sponsor":"John","startDate":"","conditions":"Drug Resistant Epilepsy","enrollment":""},{"nctId":"NCT04642404","phase":"PHASE1, PHASE2","title":"CBD for Dental Pain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2021-03-01","conditions":"Odontalgia, Toothache","enrollment":64},{"nctId":"NCT05407285","phase":"PHASE1, PHASE2","title":"A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-07-22","conditions":"Cannabis","enrollment":70},{"nctId":"NCT03941288","phase":"PHASE2","title":"Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-09-04","conditions":"Gastroparesis, Dyspepsia","enrollment":92},{"nctId":"NCT03196934","phase":"","title":"Expanded Use of Cannabidiol Oral Solution","status":"NO_LONGER_AVAILABLE","sponsor":"MultiCare Health System Research Institute","startDate":"","conditions":"Refractory Epilepsy","enrollment":""},{"nctId":"NCT05892276","phase":"NA","title":"Effects of CBD Oil on Memory Reconsolidation and Trauma-Related Symptoms","status":"WITHDRAWN","sponsor":"University of Texas at Austin","startDate":"2024-08-31","conditions":"Posttraumatic Stress Disorder","enrollment":""},{"nctId":"NCT03467113","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol","status":"COMPLETED","sponsor":"Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.","startDate":"2018-01-19","conditions":"Dravet Syndrome, Lennox Gastaut Syndrome","enrollment":9},{"nctId":"NCT02783092","phase":"PHASE3","title":"A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy","status":"UNKNOWN","sponsor":"Antonio Waldo Zuardi","startDate":"2019-01-09","conditions":"Epilepsy","enrollment":126},{"nctId":"NCT05098509","phase":"PHASE2, PHASE3","title":"A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2022-04-13","conditions":"Prader-Willi Syndrome","enrollment":4},{"nctId":"NCT04982029","phase":"PHASE2","title":"Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-04-14","conditions":"Opioid-use Disorder","enrollment":15},{"nctId":"NCT04238754","phase":"PHASE1, PHASE2","title":"Oral Cannabidiol for Opioid Withdrawal","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-11-01","conditions":"Opioid Withdrawal, Opioid Craving, Opioid Use Disorder","enrollment":3},{"nctId":"NCT02844933","phase":"PHASE2","title":"Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2018-05-09","conditions":"Prader-Willi Syndrome","enrollment":7},{"nctId":"NCT03336242","phase":"PHASE2","title":"Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2017-12-29","conditions":"Childhood Absence Epilepsy","enrollment":20},{"nctId":"NCT03458416","phase":"PHASE2","title":"A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2018-09-06","conditions":"Prader-Willi Syndrome","enrollment":2},{"nctId":"NCT03355300","phase":"PHASE2","title":"Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2018-02-20","conditions":"Childhood Absence Epilepsy","enrollment":11},{"nctId":"NCT04421456","phase":"PHASE2","title":"Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-08-18","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT03421496","phase":"PHASE3","title":"A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2018-09-05","conditions":"Infantile Spasm","enrollment":2},{"nctId":"NCT04447846","phase":"PHASE2","title":"Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome","status":"COMPLETED","sponsor":"Anne Comi, MD","startDate":"2019-10-14","conditions":"Sturge-Weber Syndrome","enrollment":11},{"nctId":"NCT04192370","phase":"PHASE2","title":"Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-08-03","conditions":"Opioid-use Disorder","enrollment":8},{"nctId":"NCT05803434","phase":"PHASE2","title":"Cannabidiol in Children and Young Adults With Rare Disease-associated Severe Epilepsy","status":"UNKNOWN","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2023-06-01","conditions":"Epilepsy, Rare Diseases","enrollment":30},{"nctId":"NCT02607904","phase":"PHASE2","title":"An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-12-15","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02607891","phase":"PHASE2","title":"A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-11-09","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT05387798","phase":"PHASE3","title":"A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome","status":"WITHDRAWN","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2023-01","conditions":"Prader-Willi Syndrome","enrollment":""},{"nctId":"NCT02565108","phase":"PHASE2","title":"A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-01-20","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT02224690","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-04-28","conditions":"Epilepsy, Lennox-Gastaut Syndrome","enrollment":171},{"nctId":"NCT02564952","phase":"PHASE2","title":"An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-03-11","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02544763","phase":"PHASE3","title":"A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-04-06","conditions":"Tuberous Sclerosis Complex, Seizures","enrollment":224},{"nctId":"NCT02091206","phase":"PHASE2","title":"A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-10-22","conditions":"Epilepsy, Dravet Syndrome","enrollment":34},{"nctId":"NCT02091375","phase":"PHASE3","title":"Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-03-30","conditions":"Epilepsy, Dravet Syndrome","enrollment":120},{"nctId":"NCT02224703","phase":"PHASE3","title":"GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-04-13","conditions":"Epilepsy, Dravet Syndrome","enrollment":199},{"nctId":"NCT02006628","phase":"PHASE2","title":"A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-02-25","conditions":"Schizophrenia, Schizophrenia-related Psychotic Disorder","enrollment":88},{"nctId":"NCT02224560","phase":"PHASE3","title":"Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-06-08","conditions":"Epilepsy, Lennox Gastaut Syndrome","enrollment":225},{"nctId":"NCT02953548","phase":"PHASE3","title":"Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2017-04-24","conditions":"Infantile Spasms","enrollment":9},{"nctId":"NCT03848832","phase":"PHASE3","title":"Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-07-29","conditions":"Rett Syndrome, RTT","enrollment":29},{"nctId":"NCT02954887","phase":"PHASE3","title":"Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2017-05-12","conditions":"Infantile Spasms","enrollment":9},{"nctId":"NCT04133480","phase":"PHASE4","title":"Investigation of Cognitive Outcomes With Cannabidiol Oral Solution","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2020-10","conditions":"Lennox-Gastaut Syndrome","enrollment":""},{"nctId":"NCT04252586","phase":"PHASE3","title":"A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-02-28","conditions":"Rett Syndrome, RTT","enrollment":21},{"nctId":"NCT02544750","phase":"PHASE3","title":"An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-08-31","conditions":"Tuberous Sclerosis Complex, Seizures","enrollment":199},{"nctId":"NCT03891264","phase":"PHASE4","title":"Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-13","conditions":"Back Pain, Low","enrollment":7},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT02332655","phase":"PHASE1, PHASE2","title":"Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome","status":"COMPLETED","sponsor":"Anne Comi, MD","startDate":"2014-12","conditions":"Sturge-Weber Syndrome","enrollment":5},{"nctId":"NCT04726475","phase":"PHASE1, PHASE2","title":"Impact of CBD-Rich Oil on Aversive Memory Reconsolidation","status":"UNKNOWN","sponsor":"University of Texas at Austin","startDate":"2022-01","conditions":"Anxiety and Fear","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo","Arvisol"],"phase":"phase_3","status":"active","brandName":"Cannabidiol oral solution","genericName":"Cannabidiol oral solution","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabidiol modulates endocannabinoid signaling and multiple other pathways to reduce seizure activity and provide neuroprotective effects. Used for Seizures associated with Dravet syndrome, Seizures associated with Lennox-Gastaut syndrome, Seizures associated with tuberous sclerosis complex.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}